Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neurogene Inc. - Common Stock (NQ: NGNE )

48.59 +4.18 (+9.41%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 195,764
Open 44.89
Bid (Size) 38.45 (3)
Ask (Size) 50.00 (1)
Prev. Close 44.41
Today's Range 44.37 - 51.30
52wk Range 12.49 - 53.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NGNE Stock Earnings: Neurogene Misses EPS for Q2 2024
NGNE stock results show that Neurogene missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates
From Neurogene Inc.
Via Business Wire

Performance

YTD
+144.54%
+144.54%
1 Month
+41.33%
+41.33%
3 Month
+32.07%
+32.07%
6 Month
+16.75%
+16.75%
1 Year
+221.79%
+221.79%

More News

Read More
Neurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett Syndrome
From Neurogene Inc.
Via Business Wire
Neurogene to Participate in BMO Genetic Medicines Summit
From Neurogene Inc.
Via Business Wire
MicroMarvel Neurogene Challenges Big Pharma
Via Talk Markets
Neurogene Announces Addition to Russell 3000® Index
From Neurogene Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
From Neurogene Inc.
Via Business Wire
Neurogene to Participate in Upcoming Conferences
From Neurogene Inc.
Via Business Wire
Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program
From Neurogene Inc.
Via Business Wire
NGNE Stock Earnings: Neurogene Beats EPS for Q1 2024
Via InvestorPlace
Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates
From Neurogene Inc.
Via Business Wire
Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting
From Neurogene Inc.
Via Business Wire
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
From Neurogene Inc.
Via Business Wire
7 A-Rated Aggressive Biotech Stocks to Bet On in 2024
Via InvestorPlace
Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates
From Neurogene Inc.
Via Business Wire
Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial
From Neurogene Inc.
Via Business Wire
Neurogene to Participate in Upcoming Investor Conferences
From Neurogene Inc.
Via Business Wire
Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer
From Neurogene Inc.
Via Business Wire
Neurogene Announces Business Update and 2024 Outlook
From Neurogene Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.